JP2002531418A - アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物 - Google Patents

アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物

Info

Publication number
JP2002531418A
JP2002531418A JP2000584922A JP2000584922A JP2002531418A JP 2002531418 A JP2002531418 A JP 2002531418A JP 2000584922 A JP2000584922 A JP 2000584922A JP 2000584922 A JP2000584922 A JP 2000584922A JP 2002531418 A JP2002531418 A JP 2002531418A
Authority
JP
Japan
Prior art keywords
virion
polyoxyethylene sorbitan
tween
pharmaceutical composition
sorbitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000584922A
Other languages
English (en)
Japanese (ja)
Inventor
ヘマ エス． シスタ，
エロ ジェイ． エスピノーザ，
Original Assignee
アビジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アビジェン， インコーポレイテッド filed Critical アビジェン， インコーポレイテッド
Publication of JP2002531418A publication Critical patent/JP2002531418A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2000584922A 1998-12-03 1999-12-02 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物 Pending JP2002531418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11068998P 1998-12-03 1998-12-03
US60/110,689 1998-12-03
PCT/US1999/028460 WO2000032233A2 (en) 1998-12-03 1999-12-02 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010274133A Division JP5663285B2 (ja) 1998-12-03 2010-12-08 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物

Publications (1)

Publication Number Publication Date
JP2002531418A true JP2002531418A (ja) 2002-09-24

Family

ID=22334360

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000584922A Pending JP2002531418A (ja) 1998-12-03 1999-12-02 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2010274133A Expired - Lifetime JP5663285B2 (ja) 1998-12-03 2010-12-08 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2014000095A Withdrawn JP2014058578A (ja) 1998-12-03 2014-01-06 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2015241786A Withdrawn JP2016040330A (ja) 1998-12-03 2015-12-11 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2017157878A Pending JP2017206556A (ja) 1998-12-03 2017-08-18 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010274133A Expired - Lifetime JP5663285B2 (ja) 1998-12-03 2010-12-08 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2014000095A Withdrawn JP2014058578A (ja) 1998-12-03 2014-01-06 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2015241786A Withdrawn JP2016040330A (ja) 1998-12-03 2015-12-11 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
JP2017157878A Pending JP2017206556A (ja) 1998-12-03 2017-08-18 アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物

Country Status (9)

Country Link
EP (1) EP1144009B1 (enExample)
JP (5) JP2002531418A (enExample)
AT (1) ATE226449T1 (enExample)
AU (2) AU773834B2 (enExample)
CA (1) CA2353417C (enExample)
DE (1) DE69903666T2 (enExample)
ES (1) ES2185417T3 (enExample)
PT (1) PT1144009E (enExample)
WO (1) WO2000032233A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
JP2023113623A (ja) * 2019-04-19 2023-08-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002229823B2 (en) * 2001-04-04 2007-02-15 Delsitech Oy Biodegradable carrier and method for preparation thereof
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
US8980610B2 (en) * 2008-11-20 2015-03-17 Biogen Idec Ma Inc. Arginine inactivation of viruses
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
EP4008356A1 (en) 2016-03-31 2022-06-08 University of Cincinnati Methods and compositions for the treatment of als
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
WO2018212271A1 (ja) 2017-05-18 2018-11-22 国立大学法人京都大学 脊髄小脳変性症３６型の予防又は治療用組成物
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO1998002522A1 (fr) * 1996-07-16 1998-01-22 Transgene S.A. Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998009524A1 (en) * 1996-09-06 1998-03-12 Chiron Corporation Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO1998002522A1 (fr) * 1996-07-16 1998-01-22 Transgene S.A. Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998009524A1 (en) * 1996-09-06 1998-03-12 Chiron Corporation Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
JP2023113623A (ja) * 2019-04-19 2023-08-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP7669414B2 (ja) 2019-04-19 2025-04-28 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法

Also Published As

Publication number Publication date
PT1144009E (pt) 2003-01-31
AU2036100A (en) 2000-06-19
CA2353417C (en) 2008-04-22
ES2185417T3 (es) 2003-04-16
DE69903666T2 (de) 2003-07-03
JP2011046748A (ja) 2011-03-10
JP2016040330A (ja) 2016-03-24
JP5663285B2 (ja) 2015-02-04
AU2004205308A1 (en) 2004-09-23
EP1144009B1 (en) 2002-10-23
ATE226449T1 (de) 2002-11-15
CA2353417A1 (en) 2000-06-08
EP1144009A3 (en) 2002-02-06
DE69903666D1 (de) 2002-11-28
AU773834B2 (en) 2004-06-10
EP1144009A2 (en) 2001-10-17
JP2014058578A (ja) 2014-04-03
WO2000032233A2 (en) 2000-06-08
WO2000032233A3 (en) 2001-10-18
JP2017206556A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
US7598070B2 (en) Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
JP5663285B2 (ja) アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
KR102526711B1 (ko) 고효율 게놈 편집을 위한 아데노-관련 바이러스 벡터 변이체 및 이의 방법
JP7196104B2 (ja) 増強された改変ウイルスカプシドタンパク質
US20080279945A1 (en) Gel-based delivery of recombinant adeno-associated virus vectors
KR20220012249A (ko) 조작 aav
Chen et al. Targeting transgene to the heart and liver with AAV 9 by different promoters
EP0874904A1 (en) Methods for delivering dna to muscle cells using recombinant adenoassociated virus virions
WO1997026337A9 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
JP2002516345A (ja) 第ｖｉｉｉ因子活性のアデノ随伴ウイルスベクター媒介性発現
JP2001512142A (ja) 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法
CN118434877A (zh) 用于核纤层蛋白a相关缺陷的基因疗法
JP2021529001A (ja) レーベル遺伝性視神経症を治療するための組成物及び方法
US20250195693A1 (en) Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same
EP4613861A1 (en) Expression cassette for target gene and use thereof
CN120584187A (zh) 腺相关病毒制剂
US20230175014A1 (en) Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
HK40092260A (zh) 用於治疗由於nd4突变造成的莱伯氏遗传性视神经病变的组合物和方法
WO2025076463A1 (en) Gene therapy for lafora disease
CN116024266A (zh) 用于治疗由于nd4突变造成的莱伯氏遗传性视神经病变的组合物和方法
CN117281923A (zh) 包含aav的药物组合物及其制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110928